Brexit nerves prompt medicines stockpiling in Europe

2 August 2018

Sanofi (Euronext: SAN) and Novartis (SIX: NOVN) have announced that they are forming plans to stockpile months' worth of drugs in UK facilities ahead of the country's uncertain departure from the European Union in March 2019.

They are the latest in a series of manufacturers to announce contingency plans for Brexit, with Roche (SIX: ROG), AstraZeneca (LSE: SIX), Pfizer (NYSE: PFE) and Eisai (TYO: 4523), according to various media report.

Hugo Fry, managing director of Sanofi UK, said that the French pharma major had taken steps to ensure that British patients would receive continuous care for months after the date of departure regardless of the political climate.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK